News stories about C R Bard (NYSE:BCR) have trended somewhat positive on Friday, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. C R Bard earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 44.91306927705 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

BCR has been the topic of several research analyst reports. Zacks Investment Research raised shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price objective on the stock in a research report on Tuesday, December 26th. ValuEngine lowered shares of C R Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $320.83.

C R Bard has a 1 year low of $223.02 and a 1 year high of $337.73. The stock has a market capitalization of $24,140.00, a P/E ratio of 43.64, a PEG ratio of 2.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72.

In related news, VP John A. Deford sold 14,107 shares of the firm’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $333.48, for a total transaction of $4,704,402.36. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.80% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This report was posted by Marea Informative and is the property of of Marea Informative. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at

About C R Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with's FREE daily email newsletter.